Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” the article reads. “The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications.”
To view the full article, visit https://nnw.fm/hJ5Bd
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://nnw.fm/SILO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork